Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
brentuximab vedotin + lenalidomide + rituximab
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
**Brentuximab vedotin + lenalidomide + rituximab** is a combination therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are ineligible for autologous hematopoietic stem cell transplantation or CAR T-cell therapy. - **Brentuximab vedotin** is an antibody-drug conjugate (ADC) targeting CD30, in which a monoclonal antibody is linked to the cytotoxic agent monomethyl auristatin E. It delivers the cytotoxic agent to CD30-expressing cells, leading to cell death. - **Lenalidomide** is an immunomodulatory small molecule that exerts antineoplastic activity through multiple mechanisms, including inhibition of angiogenesis, modulation of the immune response, and direct cytotoxicity to tumor cells. - **Rituximab** is a monoclonal antibody targeting CD20 on B lymphocytes, resulting in B-cell depletion through cytotoxic and apoptotic mechanisms[1][2][4][5][7][8]. This combination demonstrated a statistically significant survival benefit in patients with relapsed/refractory DLBCL in phase 3 clinical trials.
- Other names
- brentuximab vedotin + lenalidomide + rituximab
02
Targets
Beyond the preview
Go deeper on brentuximab vedotin + lenalidomide + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on brentuximab vedotin + lenalidomide + rituximab.